Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy
Open accessPublished version of a preprint
Abstract
Abstract Despite advances in immuno-oncology, the relationship between tumor genotypes and response to immunotherapy remains poorly understood, particularly in high-grade serous tubo-ovarian carcinomas (HGSC). We developed a series of mouse models that carry genotypes of human HGSCs and grow in syngeneic immunocompetent hosts to address this gap. We transformed murine-fallopian tube epithelial cells to phenocopy homologous recombination–deficient tumors through a combined loss of Trp53, Brca1, Pten, and Nf1 and overexpression of Myc and Trp53R172H, which was contrasted with an identical model carrying wild-type Brca1. For homologous recombination–proficient tumors, we constructed genotypes combining loss of Trp53 and overexpression of Ccne1, Akt2, and Trp53R172H, and driven by KRASG12V or Brd4 or Smarca4 overexpression. These lines form tumors recapitulating human disease, including genotype-driven responses to treatment, and enabled us to identify follistatin as a driver of resistance to checkpoint inhibitors. These data provide proof of concept that our models can identify new immunotherapy targets in HGSC. Significance: We engineered a panel of murine fallopian tube epithelial cells bearing mutations typical of HGSC and capable of forming tumors in syngeneic immunocompetent hosts. These models recapitulate tumor microenvironments and drug responses characteristic of human disease. In a Ccne1-overexpressing model, immune-checkpoint resistance was driven by follistatin. This article is highlighted in the In This Issue feature, p. 211
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Generation of multiple fallopian tube epithelial cell lines with combinations of common mutations in high-grade serous ovarian cancer using CRISPR/Cas9 recapitulated histopathological and clinical features observed in HGSOC patients, such as ascites and peritoneal metastases.
“Generation of multiple fallopian tube epithelial cell lines with combinations of common mutations in HGSOC (Tp53, Brca1, Brca2, Ccne1, Akt2, Brd4, Smarca4, Kras, Myc, Nf1, and Pten) using CRISPR/Cas9 recapitulated histopathological and clinical features observed in HGSOC patients, such as ascites and peritoneal metastases (Iyer et al., 2021).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Iyer et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · see citing works
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · see citing works
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · see citing works
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219 · see citing works
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927 · see citing works
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422 · see citing works
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652 · see citing works
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 2× · see citing works
“S3I), indicative once again of impaired effector T-cell functions (36, 37).”
BackgroundVignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463 · see citing works
Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells
Klein, A. M., Mazutis, L., Akartuna, I., Tallapragada, N., Veres, A., Li, V., Peshkin, L., Weitz, D. A., & Kirschner, M. W. (2015) · Cell · doi:10.1016/j.cell.2015.04.044 · Cited by 3,356 · see citing works
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · see citing works
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
Corces, M. R., Trevino, A. E., Hamilton, E. G., Greenside, P. G., Sinnott-Armstrong, N. A., Vesuna, S., Satpathy, A. T., Rubin, A. J., Montine, K. S., Wu, B., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4396 · Cited by 2,496 · see citing works
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.49 · Cited by 2,217 · see citing works
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008 · see citing works
Ovarian Cancer Development and Metastasis
Lengyel, E. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,679 · see citing works
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517 · see citing works
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,365 · see citing works
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355 · see citing works
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207 · see citing works
T-cell exhaustion in the tumor microenvironment
Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.162 · Cited by 1,151 · see citing works
TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
Yang, L., Pang, Y., & Moses, H. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.002 · Cited by 1,023 · see citing works
Boeva, V., Popova, T. G., Kevin Bleakley, A., Chiche, P., Cappo, J., Schleiermacher, G., Janoueix‐Lerosey, I., Delattre, O., & Barillot, E. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr670 · Cited by 1,012 · see citing works
Essential role for nuclear PTEN in maintaining chromosomal integrity
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. (2007) · Cell · doi:10.1016/j.cell.2006.11.042 · Cited by 979 · see citing works
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · see citing works
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902 · see citing works
Matulonis, U. A., Shapira‐Frommer, R., Santin, A. D., Lisyanskaya, A. S., Pignata, S., Vergote, I. B., Raspagliesi, F., Sonke, G. S., Birrer, M. J., Provencher, D. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz135 · Cited by 856 · see citing works
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 830 · see citing works
Abkevich, V., Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith‐McCune, K., Broaddus, R. R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 818 · see citing works
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Mendes‐Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, J., Waldman, T. A., Lord, C. J., & Ashworth, A. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900041 · Cited by 630 · see citing works
Strickland, K. C., Howitt, B. E., Shukla, S. A., Rodig, S. J., Ritterhouse, L. L., Liu, J. F., Garber, J. E., Chowdhury, D., Wu, C. J., D’Andrea, A. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7277 · Cited by 621 · see citing works
Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.013 · Cited by 596 · see citing works
Development of a Syngeneic Mouse Model for Events Related to Ovarian Cancer
Roby, K. F., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., & Terranova, P. F. (2000) · Carcinogenesis · doi:10.1093/carcin/21.4.585 · Cited by 593 · see citing works
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572 · see citing works
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Kipps, E., Tan, D. S., & Kaye, S. (2013) · Nature Reviews. Cancer · doi:10.1038/nrc3432 · Cited by 552 · see citing works
SynergyFinder: a web application for analyzing drug combination dose–response matrix data
Ianevski, A., He, L., Aittokallio, T. A., & Tang, J. P. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx162 · Cited by 535 · see citing works
Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption
Lanni, J. S., & Jacks, T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.1055 · Cited by 493 · see citing works
Liu, X., Holstege, H. H., van der Gulden, H. M. L., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R. M., van Vliet, M. H., Wessels, L. F. A., Peterse, J. L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702969104 · Cited by 474 · see citing works
Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 449 · see citing works
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448 · see citing works
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
Disis, M. L., Taylor, M. H., Kelly, K. L., Beck, J. T., Gordon, M. S., Moore, K. M., Patel, M. R., Chaves, J. M., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 438 · see citing works
High-grade serous ovarian cancer arises from fallopian tube in a mouse model
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117135109 · Cited by 400 · see citing works
PTEN: a new guardian of the genome
Yin, Y., & Shen, W. H. (2008) · Oncogene · doi:10.1038/onc.2008.241 · Cited by 386 · see citing works
ATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 378 · see citing works
Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821218116 · Cited by 359 · cited 1× · see citing works
“We additionally investigated CTLA4 inhibition (51), which can inhibit Treg function (elevated in KPCA tumors) and can promote T-cell infiltration (low in KPCA tumors; Fig.”
BackgroundLessons from BRCA: the Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer
Crum, C. P., Drapkin, R., Kindelberger, D., Medeiros, F., Miron, A., & Lee, Y. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.702 · Cited by 342 · see citing works
Sztupinszki, Z. M., Dióssy, M., Krzystanek, M., Reiniger, L., Csabai, I., Favero, F., Birkbak, N. J., Eklund, A. C., Syed, A., & Szállási, Z. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0066-6 · Cited by 310 · see citing works
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
Färkkilä, A., Gulhan, D., Casado, J., Jacobson, C. A., Nguyen, H. Q., Kochupurakkal, B. S., Maliga, Z., Yapp, C., Chen, Y., Schapiro, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15315-8 · Cited by 302 · see citing works
Mutation detection using Surveyor™ nuclease
Qiu, P., Shandilya, H., D'Alessio, J. M., O’Connor, K. C., Durocher, J. A., & Gerard, G. F. (2004) · BioTechniques · doi:10.2144/04364pf01 · Cited by 299 · see citing works
Modeling High-Grade Serous Ovarian Carcinogenesis from the Fallopian Tube
Karst, A. M., Levanon, K., & Drapkin, R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017300108 · Cited by 280 · see citing works
Jiménez-Sánchez, A., Cybulska, P., Mager, K. L., Koplev, S., Cast, O. M., Couturier, D., Memon, D., Selenica, P., Nikolovski, I., Mazaheri, Y., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0630-5 · Cited by 244 · see citing works
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239 · see citing works
Zhang, S., Dolgalev, I., Zhang, T., Ran, H., Levine, D. A., & Neel, B. G. (2019) · Nature Communications · doi:10.1038/s41467-019-13116-2 · Cited by 235 · see citing works
Walton, J. B., Blagih, J., Ennis, D. P., Leung, E. Y. L., Dowson, S., Farquharson, M., Tookman, L. A., Orange, C., Athineos, D., Mason, S. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1272 · Cited by 232 · see citing works
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Etemadmoghadam, D., Weir, B. A., Au‐Yeung, G., Alsop, K., Mitchell, G., George, J., Australian Ovarian Cancer Study Group, Davis, S. J., D’Andrea, A. D., Simpson, K. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314302110 · Cited by 225 · see citing works
Lee, J., Nair, J. R., Zimmer, A. S., Lipkowitz, S., Annunziata, C. M., Merino, M. J., Swisher, E. M., Harrell, M. I., Trepel, J. B., Lee, M.-J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30009-3 · Cited by 207 · see citing works
Giuntoli, R. L., Webb, T. J., Zoso, A., Rogers, O. C., Diaz-Montes, T. P., Bristow, R. E., & Oelke, M. (2009) · PubMed · Cited by 195 · see citing works
The Regulation and Functions of Activin and Follistatin in Inflammation and Immunity
Hedger, M. P., Winnall, W. R., Phillips, D. J., & de Kretser, D. M. (2011) · Vitamins and hormones · doi:10.1016/b978-0-12-385961-7.00013-5 · Cited by 177 · see citing works
Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway
Lee, J., Ahn, E., Kissick, H. T., & Ahmed, R. (2015) · Forum on Immunopathological Diseases and Therapeutics · doi:10.1615/forumimmundisther.2015014188 · Cited by 165 · see citing works
The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding
Cash, J. N., Rejon, C. A., McPherron, A. C., Bernard, D. J., & Thompson, T. B. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.205 · Cited by 159 · see citing works
Park, M.-J., Lee, S., Kim, E., Lee, E., Baek, J.-A., Park, S., Kwok, S., & Cho, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-21856-2 · Cited by 156 · see citing works
Activin-A in the regulation of immunity in health and disease
Morianos, I., Papadopoulou, G., Semitekolou, M., & Xanthou, G. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102314 · Cited by 150 · see citing works
Au‐Yeung, G., Lang, F., Azar, W. J., Mitchell, T. J., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C. M., Pearson, R. B., Mileshkin, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 147 · see citing works
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129 · see citing works
The bright and the dark sides of activin in wound healing and cancer
Antsiferova, M. A., & Werner, S. (2012) · Journal of Cell Science · doi:10.1242/jcs.094789 · Cited by 108 · see citing works
Gu, L., Deng, Z. J., Roy, S., & Hammond, P. T. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2186 · Cited by 98 · see citing works
High‐grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease
Zhai, Y., WU, R. T., Kuick, R. D., Sessine, M. S., Schulman, S., Green, M., Fearon, E. R., & Cho, K. R. (2017) · The Journal of Pathology · doi:10.1002/path.4927 · Cited by 95 · see citing works
Zhang, S., Iyer, S., Ran, H., Dolgalev, I., Gu, S. S., Wei, W., Foster, C., Loomis, C. A., Olvera, N., Dao, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0455 · Cited by 88 · see citing works
O'Connor, L. O., Rulten, S., Cranston, A., Odedra, R., Brown, H., Jaspers, J., Jones, L. A., Knights, C., Evers, B., Ting, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3240 · Cited by 83 · see citing works
Kampan, N. C., Madondo, M., McNally, O., Stephens, A. N., Quinn, M. A., & Plebanski, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01482 · Cited by 75 · see citing works
Opportunities in immunotherapy of ovarian cancer
Coukos, G., Tanyi, J. L., & Kandalaft, L. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw084 · Cited by 74 · see citing works
High Serum Levels of Follistatin in Patients with Ovarian Cancer
Ren, P., Chen, F.-F., Liu, H.-Y., Cui, X.-L., Sun, Y., Guan, J.-L., Liu, Z.-H., Liu, J.-G., & Wang, Y.-N. (2012) · Journal of International Medical Research · doi:10.1177/147323001204000306 · Cited by 57 · see citing works
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model
Álamo, P., Gallardo, A., Nicolantonio, F. D., Pavón, M. Á., Casanova, I., Trías, M., Mangues, M. A., Pousa, A. L., Villaverde, A., Vázquez, E., et al. (2014) · The FASEB Journal · doi:10.1096/fj.14-262303 · Cited by 50 · see citing works
Saatcioglu, H. D., Kano, M., Horn, H., Zhang, L., Samore, W. R., Nagykery, N. G., Meinsohn, M.-C., Hyun, M., Suliman, R., Poulo, J., et al. (2019) · eLife · doi:10.7554/elife.46349 · Cited by 48 · see citing works
Clinical and therapeutic implications of follistatin in solid tumours
SHI, L., RESAUL, J., OWEN, S., YE, L., & JIANG, W. G. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20005 · Cited by 47 · see citing works
Janat-Amsbury, M. M., Yockman, J. W., Anderson, M. L., Kieback, D., & Kim, S. W. (2006) · PubMed · Cited by 43 · see citing works
Precious GEMMs: emergence of faithful models for ovarian cancer research
Stückelberger, S., & Drapkin, R. (2018) · The Journal of Pathology · doi:10.1002/path.5065 · Cited by 28 · see citing works
Cárdenas, H., Jiang, G., Pepin, J. T., Parker, J. B., Condello, S., Nephew, K. P., Nakshatri, H., Chakravarti, D., Liu, Y., & Matei, D. E. (2019) · npj Precision Oncology · doi:10.1038/s41698-019-0103-4 · Cited by 27 · see citing works
Fazzini, M., Vallejo, G., Colman‐Lerner, A., Trigo, R., Campo, S., Barañao, J. L., & Saragüeta, P. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20533 · Cited by 22 · see citing works
RNA‐Peptide nanoplexes drug DNA damage pathways in high‐grade serous ovarian tumors
Dreaden, E. C., Kong, Y. W., Quadir, M., Correa, S., Suárez-López, L., Barberio, A. E., Hwang, M. K., Shi, A. C., Oberlton, B., Gallagher, P. N., et al. (2018) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10086 · Cited by 17 · see citing works
Current Preclinical Models of Ovarian Cancer
Tisato, E. K. V. (2015) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000220 · Cited by 13 · see citing works
Kaneko, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801028-0.00189-6 · Cited by 2 · see citing works
Flagged first, then by citations
1 of the 83 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [55]Kaneko H. Subchapter 33C - Follistatin. In: Takei Y, Ando H, Tsutsui K, editors. Handbook of Hormones. San Diego: Academic Press; 2016. p 298-e33C-2.
Cited by
Sorted by citations
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 380 · see citing works
Ovarian cancer mutational processes drive site-specific immune evasion
Vázquez-Garćıa, I., Uhlitz, F., Ceglia, N., Lim, J. L., Wu, M. K. Y., Mohibullah, N., Niyazov, J., Ruiz, A. E. B., Boehm, K. M., Bojilova, V., et al. (2022) · Nature · doi:10.1038/s41586-022-05496-1 · Cited by 318 · see citing works
Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)
Yang, L., Xie, H., Li, Y., Wang, X., Liu, X., & Mai, J. (2022) · Oncology Reports · doi:10.3892/or.2022.8293 · Cited by 315 · see citing works
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Laniti, D. D., & Coukos, G. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00503-z · Cited by 186 · see citing works
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Schoutrop, E., Moyano‐Galceran, L., Lheureux, S., Mattsson, J., Lehti, K., Dahlstrand, H. M., & Magalhaes, I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.027 · Cited by 176 · see citing works
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
Launonen, I.-M. P., Lyytikäinen, N., Casado, J., Anttila, E., Szabó, A., Haltia, U.-M., Jacobson, C. A., Lin, J., Maliga, Z., Howitt, B. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28389-3 · Cited by 112 · see citing works
FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer
Liu, C., Barger, C. J., & Karpf, A. R. (2021) · Cancers · doi:10.3390/cancers13123065 · Cited by 97 · see citing works
Shaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Barki, D., Nevo, R., Brown, L. E., Zhang, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34081-3 · Cited by 79 · see citing works
Paffenholz, S. V., Salvagno, C., Ho, Y.-J., Limjoco, M., Baslan, T., Tian, S., Kulick, A. R., de Stanchina, E., Wilkinson, J. E., Barriga, F. M., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117754119 · Cited by 90 · see citing works
Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis
Ozmadenci, D., Narayanan, J. S. S., Andrew, J. R., Ojalill, M., Barrie, A. M., Jiang, S., Iyer, S., Chen, X. L., Rose, M., Estrada, V., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2117065119 · Cited by 78 · see citing works
Transgelin 2 guards T cell lipid metabolism and antitumour function
Hwang, S., Awasthi, D., Jeong, J., Sandoval, T. A., Chae, C.-S., Ramos, Y., Chen, T., Falco, M. M., Salvagno, C., Emmanuelli, A., et al. (2024) · Nature · doi:10.1038/s41586-024-08071-y · Cited by 78 · see citing works
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity
Heide, J., Bilecz, A. J., Patnaik, S., Allega, M. F., Donle, L., Yang, K., Teich, E. A., Li, Y., Lin, Q., Kong, K., et al. (2025) · Nature · doi:10.1038/s41586-025-09303-5 · Cited by 77 · see citing works
Lee, W., Ko, S. Y., Akasaka, H., Weigert, M., Lengyel, E. R., & Naora, H. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.12.004 · Cited by 76 · see citing works
Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Leary, A. F., Tan, D. S. P., & Ledermann, J. A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211039899 · Cited by 71 · see citing works
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66 · see citing works
Konstantinopoulos, P. A., Lee, J., Gao, B., Miller, R. E., Lee, J., Colombo, N., Vergote, I. B., Credille, K. M., Young, S. R. L., McNeely, S., et al. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.09.019 · Cited by 67 · see citing works
Biology-driven therapy advances in high-grade serous ovarian cancer
Wang, Y., Duval, A. J., Adli, M., & Matei, D. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174013 · Cited by 70 · see citing works
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer
Chae, C.-S., Sandoval, T. A., Hwang, S., Park, E. S., Giovanelli, P., Awasthi, D., Salvagno, C., Emmanuelli, A., Tan, C., Chaudhary, V., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1181 · Cited by 64 · see citing works
Criscione, S. W., Martin, M. J., Oien, D. B., Gorthi, A., Miragaia, R. J., Zhang, J., Chen, H., Karl, D. L., Mendler, K., Markovets, A. A., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00337-w · Cited by 56 · see citing works
Jo, A., Green, A., Medina, J. E., Iyer, S., Öhman, A., McCarthy, E. T., Reinhardt, F., Gerton, T. J., Demehin, D., Mishra, R. K., et al. (2023) · Advanced Science · doi:10.1002/advs.202301930 · Cited by 55 · see citing works
Akinjiyan, F. A., Ibitoye, Z., Zhao, P., Shriver, L. P., Patti, G. J., Longmore, G. D., & Fuh, K. C. (2023) · Oncogene · doi:10.1038/s41388-023-02884-3 · Cited by 50 · see citing works
Mei, J., Tian, H., Huang, H.-S., Hsu, C., Liou, Y., Wu, N., Zhang, W., & Chu, T. (2021) · Cell Proliferation · doi:10.1111/cpr.13029 · Cited by 50 · see citing works
Ciucci, A., Buttarelli, M., Fagotti, A., Scambia, G., & Gallo, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04395-y · Cited by 43 · see citing works
Intra-Tumoral Nerve-Tracing in a Novel Syngeneic Model of High-Grade Serous Ovarian Carcinoma
Barr, J. L., Kruse, A., Restaino, A. C., Tulina, N. M., Stückelberger, S., Vermeer, S. J., Williamson, C. S., Vermeer, D. W., Madeo, M., Stamp, J., et al. (2021) · Cells · doi:10.3390/cells10123491 · Cited by 41 · see citing works
Nie, H., Saini, P., Miyamoto, T., Liao, L., Zielinski, R. J., Liu, H., Zhou, W., Wang, C., Murphy, B., Towers, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47069-y · Cited by 40 · see citing works
Gupta, V. G., Hirst, J. J., Harrington, S. P., Roby, K. F., Kusch, M., Zhou, H., Clive, M. L., Jewell, A., Pathak, H. B., Godwin, A. K., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.04.015 · Cited by 40 · see citing works
Mouse models for immuno-oncology
Bosenberg, M., Liu, E. T., Yu, C. I., & Palucka, K. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.03.009 · Cited by 39 · see citing works
Layer‐by‐layer interleukin‐12 nanoparticles drive a safe and effective response in ovarian tumors
Barberio, A. E., Smith, S. G., Pires, I. S., Iyer, S., Reinhardt, F., Melo, M. B., Suh, H., Weinberg, R. A., Irvine, D. J., & Hammond, P. T. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10453 · Cited by 38 · see citing works
Croft, P. K., Sharma, S., Godbole, N., Rice, G. E., & Salomón, C. (2021) · Cells · doi:10.3390/cells10092272 · Cited by 37 · see citing works
Rodriguez, G. M., Galpin, K. J. C., Cook, D. P., Yakubovich, E., Maranda, V., Macdonald, E. A., Wilson‐Sanchez, J., Thomas, A. L., Burdette, J. E., & Vanderhyden, B. C. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0017 · Cited by 32 · see citing works
Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
Cook, D. P., Galpin, K. J. C., Rodriguez, G. M., Shakfa, N. E., Wilson‐Sanchez, J., Echaibi, M., Pereira, M., Matuszewska, K., Haagsma, J., Murshed, H., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05529-z · Cited by 31 · see citing works
Li, X., Poire, A., Jeong, K. J., Zhang, D., Ozmen, T. Y., Chen, G., Sun, C., & Mills, G. B. (2024) · Nature Communications · doi:10.1038/s41467-024-48637-y · Cited by 29 · see citing works
Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Sandoval, T. A., Salvagno, C., Chae, C.-S., Awasthi, D., Giovanelli, P., Falco, M. M., Hwang, S., Terán-Cabanillas, E., Suominen, L., Yamazaki, T., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1451 · Cited by 29 · see citing works
Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
Bella, Á., Trani, C. A. D., Fernández-Sendin, M., Arrizabalaga, L., Cirella, A., Teijeira, Á., Medina‐Echeverz, J., Melero, I., Berraondo, P., & Aranda, F. (2021) · Cancers · doi:10.3390/cancers13050963 · Cited by 27 · see citing works
Schab, A. M., Greenwade, M. M., Stock, E. C., Lomonosova, E., Cho, K., Grither, W. R., Noia, H. M., Wilke, D., Mullen, M. M., Hagemann, A. R., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0347 · Cited by 25 · see citing works
Mize, B. K., Salvi, A., Ren, Y., Burdette, J. E., & Fuchs, J. R. (2023) · Natural Product Reports · doi:10.1039/d2np00091a · Cited by 25 · see citing works
Elkin, R., Oh, J. H., Liu, Y. L., Selenica, P., Weigelt, B., Reis-Filho, J. S., Zamarin, D., Deasy, J. O., Norton, L., Levine, A. J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00259-9 · Cited by 25 · see citing works
IL-12-releasing nanoparticles for effective immunotherapy of metastatic ovarian cancer
Pires, I. S., Covarrubias, G., Gomerdinger, V. F., Backlund, C. M., Bueno, E. N., Billingsley, M. M., Pryor, M. L., Shanker, A., Gordon, E., Wu, S., et al. (2025) · Nature Materials · doi:10.1038/s41563-025-02390-9 · Cited by 24 · see citing works
Emmanuelli, A., Salvagno, C., Hwang, S., Awasthi, D., Sandoval, T. A., Chae, C.-S., Cheong, J., Tan, C., Iwawaki, T., & Cubillos‐Ruiz, J. R. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2411070 · Cited by 23 · see citing works
Experimental models for ovarian cancer research
Tsang, S. I., Hassan, A. A., To, S. K. Y., & Wong, A. S. T. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113150 · Cited by 22 · see citing works
Cole, A. J., Panesso-Gómez, S., Shah, J. S., Ebai, T., Jiang, Q., Gümüşoğlu-Acar, E., Bello, M. G., Vlad, A., Modugno, F., Edwards, R. P., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2254 · Cited by 22 · see citing works
Regulatory Role of the Adipose Microenvironment on Ovarian Cancer Progression
Chehade, H., Tedja, R., Ramos, H., Bawa, T. S., Adzibolosu, N. K., Gogoi, R. P., Mor, G., & Alvero, A. B. (2022) · Cancers · doi:10.3390/cancers14092267 · Cited by 21 · see citing works
Shakfa, N. E., Li, D., Conseil, G., Lightbody, E. D., Wilson‐Sanchez, J., Hamade, A., Chenard, S. W., Jawa, N. A., Laight, B. J., Afriyie-Asante, A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006170 · Cited by 21 · see citing works
Cancer-associated mesothelial cells are regulated by the anti-Müllerian hormone axis
Chauvin, M. Y., Meinsohn, M.-C., Dasari, S., May, P., Iyer, S., Nguyen, N. M., Oliva, E., Lucchini, Z., Nagykery, N. G., Kashiwagi, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112730 · Cited by 21 · see citing works
Park, J., Kim, J. C., Lee, Y. J., Kim, S., Seo, M.-K., Kim, S. W., Shin, E., Lee, J., & Park, S. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009058 · Cited by 21 · see citing works
The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions
Cheng, Z., Ennis, D. P., Lu, B., Mirza, H., Sokota, C., Kaur, B. S., Singh, N., Saux, O. L., Russo, G., Giannone, G., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6322 · Cited by 20 · see citing works
Dai, Y., Xu, J., Gong, X., Wei, J., Gao, Y., Chai, R., Lu, C., Zhao, B. T., & Kang, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020886 · Cited by 20 · see citing works
Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer
Mishra, A., Ye, T., Banday, S., Thakare, R., Su, C. T.-T., Pham, N., Ali, A., Kulshreshtha, A., Chowdhury, S., Simone, T. M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114041 · Cited by 19 · see citing works
Neuhaus, F., Lieber, S., Shinkevich, V. A., Steitz, A. M., Raifer, H., Roth, K., Finkernagel, F., Worzfeld, T., Burchert, A., Keber, C. U., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1604 · Cited by 18 · see citing works
Kressin, M., Fietz, D., Becker, S., & Strebhardt, K. (2021) · Cells · doi:10.3390/cells10051176 · Cited by 18 · see citing works
Myeloid activation clears ascites and reveals IL27-dependent regression of metastatic ovarian cancer
Murphy, B., Miyamoto, T., Manning, B. S., Mirji, G., Ugolini, A., Kannan, T., Hamada, K., Zhu, Y. P., Claiborne, D. T., Huang, L., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231967 · Cited by 19 · see citing works
Geng, T., Zheng, M., Wang, Y., Reseland, J. E., & SAMARA, A. A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1200354 · Cited by 17 · see citing works
Gu, S. S., Lheureux, S., Sayad, A., Cybulska, P., Hogen, L. F., Vyarvelska, I., Tu, D., Parulekar, W. R., Nankivell, M. G., Kehoe, S. T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026663118 · Cited by 17 · see citing works
Zhang, X., Dai, X., Liu, A., Sun, M., Cong, L., Liang, J., Liu, Z., Li, Z., Zhang, J., Lv, J., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03801-5 · Cited by 15 · see citing works
Zhang, X., Wang, A., Han, L. M., Liang, B., Allard, G. M., Diver, E., & Howitt, B. E. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100106 · Cited by 14 · see citing works
Stojanovic, L., Abbotts, R., Tripathi, K. K., Coon, C. M., Rajendran, S., Farid, E. A., Hostetter, G. H., Guarnieri, J. W., Wallace, D. C., Liu, S., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-1286 · Cited by 15 · see citing works
Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC
Cattolico, C., Bailey, P., & Barry, S. T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.816517 · Cited by 14 · see citing works
Chowdhury, S. R., Parikh, C. N., Kaur, A. N., DeMarco, K. D., Giwa, H. K., Mishra, A., Murphy, K. C., Zhou, L., Ma, B., Ye, T., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2514948122 · Cited by 12 · see citing works
Rethinking ovarian cancer III: the past decade and future directions
Balkwill, F. R., Laumont, C. M., Burdett, N. L., Saux, O. L., Garsed, D. W., Grither, W. R., Nijhuis, A. M., Recouvreux, M. S., Kang, Z., Zhang, R., et al. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00916-0 · Cited by 12 · see citing works
Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
Yang, S., Green, A., Virani, N. A., Robinson, A., Senat, M., Testino, B., Dinulescu, D. M., & Sridhar, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1175617 · Cited by 12 · see citing works
Localized In Vivo Prodrug Activation Using Radionuclides
Quintana, J. M., Jiang, F., Kang, M., Onecha, V. V., Könik, A., Qin, L., Rodriguez, V. E., Hu, H., Borges, N., Khurana, I., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268559 · Cited by 11 · see citing works
Steitz, A. M., Schröder, C., Knuth, I., Keber, C. U., Sommerfeld, L., Finkernagel, F., Jansen, J. M., Wagner, U. A. G., Müller‐Brüsselbach, S., Worzfeld, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108401 · Cited by 11 · see citing works
Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancerPreprint
Launonen, I.-M. P., Erkan, E. P., Niemiec, I., Junquera, A., Hincapié-Otero, M. M., Afenteva, D., Liang, Z., Salko, M., Szabo, A., Pérez‐Villatoro, F., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.19.585657 · Cited by 11 · see citing works
Leveraging dysregulated tumor metabolism for targeting anticancer bacteria
Santos, A., Wang, Z., Bharti, R., Dey, G., Sangwan, N., Baldwin, W. M., Zalavadia, A. H., Myers, A., Huffman, O. G., Lathia, J. D., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads1630 · Cited by 10 · see citing works
Babalola, B. A., Adebami, G. E., & Akinsuyi, O. (2021) · Global Journal of Cancer Therapy · doi:10.17352/2581-5407.000040 · Cited by 10 · see citing works
Launonen, I.-M. P., Vähärautio, A., & Färkkilä, A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041314 · Cited by 10 · see citing works
Gerton, T. J., Green, A., Campisi, M., Chen, M., Gjeci, I., Mahadevan, N. R., Lee, C. A. A., Mishra, R., Vo, H. V., Haratani, K., et al. (2023) · Cancers · doi:10.3390/cancers15164128 · Cited by 7 · see citing works
The Reign of Follistatin in Tumors and Their Microenvironment: Implications for Drug Resistance
Sosa, J., Oyelakin, A., & Sinha, S. (2024) · Biology · doi:10.3390/biology13020130 · Cited by 7 · see citing works
Cycling molecular assemblies for Golgi imaging and disruption
Tan, W., Zhang, Q., Liu, Z., Qiu, K., Mahajan, D., Gerton, T. J., Copperman, N., Dresselhaus, E. C., Xia, C., Lin, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68768-8 · Cited by 6 · see citing works
Kefas, J., & Flynn, M. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.67 · Cited by 6 · see citing works
Cavarzerani, E., Caligiuri, I., Bartoletti, M., Corona, G., Perin, T., Palumbo, A., Ditto, A., Occhiali, T., Canzonieri, V., & Rizzolio, F. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.009 · Cited by 6 · see citing works
Oyelakin, A., Sosa, J., Nayak, K. B., Glathar, A. R., Gluck, C. B., Sethi, I., Tsompana, M., Nowak, N. J., Buck, M. J., Romano, R., et al. (2023) · NAR Cancer · doi:10.1093/narcan/zcad038 · Cited by 5 · see citing works
Profiling extracellular vesicles in circulation enables the early detection of ovarian cancerPreprint
Jo, A., Green, A., Medina, J. E., Iyer, S., Öhman, A., McCarthy, E. T., Reinhardt, F., Gerton, T. J., Demehin, D., Mishra, R. K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.19.524549 · Cited by 5 · see citing works
Lan, H., Zhu, J., Hou, H., Zhang, C., Huo, X., Zhang, Y., Yang, F., Zhou, N., & Zhang, X. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02146-7 · Cited by 4 · see citing works
Transglutaminase 2 regulates ovarian cancer metastasis by modulating the immune microenvironment
Ibrahim, D., Grondin, M., Galpin, K. J. C., Asif, S., Thompson, E., Nersesian, S., Abou‐Hamad, J., Echaibi, M., Rodriguez, G. M., Navals, P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639853 · Cited by 3 · see citing works
AlHilli, M. M., Sangwan, N., Myers, A., Tewari, S., Lindner, D. J., Cresci, G., & Reizes, O. (2025) · Journal of Ovarian Research · doi:10.1186/s13048-025-01731-1 · Cited by 3 · see citing works
Gupta, R., Shravan, S., Agwane, S. B., Bankar, R., & Bapat, S. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-18264-8 · Cited by 3 · see citing works
Immunocompetent C57BL/6 syngeneic mouse ovarian cancer models with defined genetic alterations
Agadjanian, H., Karlan, B. Y., Walsh, C., & Oršulić, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-18960-5 · Cited by 3 · see citing works
Myeloid diversity in tumors: Shaped by genes, location, and time
Nogales-Pons, M., Munárriz-Paños, M., Aceña-Gonzalo, T., & Casanova-Acebes, M. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20252267 · Cited by 3 · see citing works
Biomaterial considerations for ovarian cancer models
Kramer, M., Criswell, A., & Sewell-Loftin, M. K. (2023) · Frontiers in Materials · doi:10.3389/fmats.2023.1223276 · Cited by 3 · see citing works
Szulta, A., Wang, L., Hasan, A., Kinter, M. T., Pranay, A., Zhu, J., Humphries, K. M., Loveland, B. L., Griffin, T. M., & Bieniasz, M. (2025) · Cancers · doi:10.3390/cancers17121942 · Cited by 3 · see citing works
Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies
Dholakia, J., Scalise, C. B., & Arend, R. C. (2021) · Cancers · doi:10.3390/cancers13071694 · Cited by 3 · see citing works
Proteomics discovery of MTDH and SND1 interaction vulnerabilities in ovarian cancer
Esmaeili, P., Nasimian, A., Werner, L., Mosquim, S., Jakobsson, M. E., Gerdtsson, A. S., Kazi, J. U., & Levander, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-26913-1 · Cited by 2 · see citing works
Miyamoto, T., Ye, Y., Soliman, M. M. H., Manning, B. S., Murphy, B., Zhu, L., Shao, C., Mirji, G., Minakuchi, M., Hamada, K., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014253 · Cited by 2 · see citing works
Experimental Modeling and Treatment Strategies for Peritoneal Carcinomatosis
Canda, A. E., & Sever, T. (2024) · Turkish Journal of Colorectal Disease · doi:10.4274/tjcd.galenos.2024.2024-10-5 · Cited by 2 · see citing works
Molecular insights into the unique properties of the blood‐circulating proteasome
Leushkin, Y., Morgenstern, D., Ben‐Dor, S., Haffner‐Krausz, R., Zittlau, K. I., Ben‐Nissan, G., & Sharon, M. (2025) · Journal of Extracellular Biology · doi:10.1002/jex2.70034 · Cited by 2 · see citing works
Cudmore, A. O., Rodriguez, G. M., Maranda, V., Boroujeni, S. F., Murshed, H., Macdonald, E. A., Grondin, M., Garson, K., Matuszewska, K., Diallo, J., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0906 · Cited by 2 · see citing works
Chauvin, M. Y., Tromelin, E., Roche-Prellezo, J., Lancia, H. H., Meinsohn, M.-C., Coletti, C. M., Nguyen, N. M., Lafont, V., Michaud, H., Mishra, R. K., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03425-4 · Cited by 4 · see citing works
Lu, W., Zhang, F., Zhong, X., Wei, J., Xiao, H., & Tu, R. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.801156 · Cited by 2 · see citing works
CD47 predominates over CD24 as a macrophage immune checkpoint in cancerPreprint
Allen, J., Meglan, A., Vaccaro, K., Velarde, J., Chen, V., Ribeiro, J., Blandin, J., Gupta, S., Mishra, R. K., Ho, R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.25.625185 · Cited by 2 · see citing works
Models of High-Grade Serous Ovarian CarcinomaPreprint
Pundel, O. J., & Neel, B. G. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041949 · Cited by 2 · see citing works
Ovarian Cancer and the Environment: Rodent Models
Vanderhyden, B. C., & Dorward, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00099-1 · Cited by 1 · see citing works
González, E. M. H., Hou, J., & Pundel, O. J. (2025) · Journal of Visualized Experiments · doi:10.3791/68753 · Cited by 1 · see citing works
Tumor Microenvironment of Epithelial Ovarian Cancer
Perkins, R. S., Choi, W.-Y., & Zhang, M. S. J. A. W. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1013212 · Cited by 2 · see citing works
Insights from three decades of BRCA1/2 modeling in mice
Darnold, J.-S., & Jonkers, J. (2026) · Nature Genetics · doi:10.1038/s41588-025-02448-z · Cited by 1 · see citing works
Rastegar‐Pouyani, N., Farzin, M. A., Karimi, P., Jafarzadeh, E., Abdolvahab, M. H., & Najafi, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128320120240805104433 · Cited by 1 · see citing works
Thirusangu, P., Jin, L., Rao, S., Ray, U., Zhao, A., Staub, J. K., Wu, X., Hou, X., VanBlaricom, J. L., Aalam, S. M. M., et al. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03180-9 · Cited by 1 · see citing works
Next generation mouse models of squamous cell lung cancer for translational immuno-oncology
Hai, J. (2020) · Oncotarget · doi:10.18632/oncotarget.27828 · Cited by 1 · see citing works
Shaashua, L., Pevsner‐Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Nevo, R., Brown, L. E., Zhang, W., Stein, Y., Kim, H. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.18.456576 · Cited by 1 · see citing works
Shakfa, N. E., Li, D., Conseil, G., Lightbody, E. D., Wilson‐Sanchez, J., Hamade, A., Chenard, S. W., Laight, B. J., Afriyie-Asante, A., Tyryshkin, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.27.497846 · Cited by 1 · see citing works
- Authors
- Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., Barrasa, M. I., Bell, G. W., Pérez-Villatoro, F., Huhtinen, K., Hynninen, J., Oikkonen, J., Galhenage, P. M., Pathania, S., Hammond, P. T., Neel, B. G., Farkkila, A., Pépin, D., & Weinberg, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- NYU Langone Health (US)
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- 1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts.
- University of Helsinki (FI)
- Harvard University (US)
- 6Research Program in Systems Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- University of Turku (FI)
- University of Massachusetts Boston (US)
- Corresponding author
- Pépin, David
- Weinberg, Robert A.
- ORCID
- Iyer, Sonia
- Zhang, Shuang
- Horn, Heiko
- Smith, Sean G.
- Assatova, Bimarzhan
- Casado, Julia
- Meinsohn, Marie-Charlotte
- Barrasa, M. Inmaculada
- Bell, George W.
- Pérez-Villatoro, Fernando
- Huhtinen, Kaisa
- Hynninen, Johanna
- Oikkonen, Jaana
- Galhenage, Pamoda M.
- Pathania, Shailja
- Hammond, Paula T.
- Neel, Benjamin G.
- Farkkila, Anniina
- Pépin, David
- Weinberg, Robert A.
- Venue
- Cancer Discovery
- Published
- 2021-02-01
- Volume
- 11
- Issue
- 2
- Pages
- 384-407
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8344888
- OpenAlex
- W3097756289
- Cited by
- 136
- References
- 83
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 24 · 2023: 21 · 2022: 22 · 2021: 13 · 2020: 3
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UTUPub (University of Turku) (submittedVersion)
- Funders
- NIH (R01 CA0784561, P01 CA080111)
- Ovarian Cancer Research Program (W81XWH-17-1-0212)
- US Army Medical Research (21702-5014)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- high-grade serous ovarian cancer, syngeneic mouse model, genetically engineered mouse models, combination immunotherapy, immunotherapy resistance, immune checkpoint inhibitors, follistatin, homologous recombination deficiency, BRCA1, PTEN, neurofibromatosis type 1, c-Myc, cyclin E1, KRAS G12V, BRD4, SMARCA4, tumor microenvironment, immunotherapy response prediction
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Disease Models, Animal, Drug Therapy, Combination, Fallopian Tube Neoplasms, Female, Mice, Transgenic, Ovarian Neoplasms, Cystadenocarcinoma, Serous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
